In clinical oncology, apart from selective targeting of HR-deficient tumour cells, PARP-1 inhibitors represent a promising tool to modulate the size of the mitochondrial population, thereby eliminating the enormous plasticity this organelle provides for tumour cells. This evidence concerns the gene PARP1 and neoplasm.